These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Contraceptive research: still inadequate after all these years?
    Author: Diconsiglio JM.
    Journal: Family Plan World; 1992; 2(6):14. PubMed ID: 12344623.
    Abstract:
    Scientists and executives at Upjohn Company stopped further research and development of prostaglandins, mainly used for contraceptive purposes, after anti-abortion groups harassed employees, destroyed property, and camped in the parking lot for weeks. 3 million women face an unplanned pregnancy yearly due to contraceptive failure. So Upjohn's retreat from contraception research adds another obstacle to any chances of a contraceptive revolution. In 1970, there were 13 major drug companies in the world (9 in the US) doing research and development on contraception. By 1987, only 4 companies were doing such research (1 in the US). So government agencies, universities, and nongovernmental and international organizations are the only groups conducting contraceptive development. They also suffer political or economic constraints. The research and approval process make any significant new contraceptive breakthrough likely to occur only after at least 10-15 years. The cost of developing a new contraceptive ranges from US$20 to 70 million and, if the cost of failed leads is added, it ranges from US$200 to 250 million. The US National Institutes of Health (NIH) and USAID conduct most contraceptive research and most of the US$165 million dedicated to it goes to basic research on reproductive physiology. In addition, contraceptive research scientists submit only 1/10,000 new chemicals identified in laboratories to the US Food and Drug Administration (FDA). So cost of applied contraceptive development and research actually equals US$30 million. The current US administration bars NIH and USAID from conducting any research on any contraceptive that is even close to abortion, e.g., RU-486. Anti-abortion groups have also motivated the government to restrict funds it distributes for contraception research to nongovernmental groups. Thus the Population Council does not have the funds to begin the approval process for its levonorgestrel releasing IUD. FDA may soon approve the female condom and Depo-Provera, however.
    [Abstract] [Full Text] [Related] [New Search]